Publications

Deep Learning Enabled 3D Multi-Omic Analysis Reveals Molecular Signatures of Heterogeneous Response to Chemotherapy in Pancreatic Cancer

Forjaz A, Mojdeganlou H, Valentin A, Wetzel M, Lvovs D, Deshpande A, Shin SM, Piya S, et al.

Dual pancreatic carcinomas: clonally related or independent primaries?

Schoenfeld JD, Ravichandran V, Tarcan Z, Sahin-Ozkan H, Richards AL, Bilani N, Chou JF, O'Connor CA, et al.

Efficacy and safety of ASP3082 monotherapy or in combination with mFOLFIRINOX in patients (pts) with pancreatic ductal adenocarcinoma (PDAC).

A Kasi, CD Lopez, C Fountzilas, S Kitano, A Hollebecque, J Berlin, ...

Efficacy and safety of cabozantinib (CABO) in advanced neuroendocrine tumors (NET) according to hormone functional status: Subgroup analysis of phase 3 CABINET trial (Alliance …

N Trikalinos, SM Geyer, T Zemla, JR Strosberg, EM Wolin, ...

Efficacy and Safety of Ifosfamide and Mesna in Metastatic Castration-Resistant Prostate Cancer after Taxane-Based Chemotherapy and Novel Hormonal Therapy Failure

Kim CG, Ko YG, Yoon J, Lee C, Beom SH, Choi YD, Han WK, Ham WS, et al.

Endoscopic Ultrasound-Guided Biomarker Evaluation of Pancreatic Cancer After Exposure to Therapy

SE Lee, D Kim, V Rolston, E Vakiani, C Sigel, EM O'reilly, K Yu, ...

ESMO podcast on upper GI cancers: highlights in hepatocellular carcinoma and pancreatic cancer from ESMO 2025

J Dekervel, A Vogel, E O’Reilly

Establishing the minimum future liver remnant volume for safe hepatectomy

JA Steinharter, J Chou, CH Ilagan, M Gönen, LV Saadat, K Soares, ...

Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma

Harvey RN, Gelfer R, Drill E, Balachandran V, D'Angelica M, Drebin J, Kingham TP, Saadat L, et al.

Evaluating the prognostic impact of IDH mutations in intrahepatic cholangiocarcinoma.

R Gelfer, R Harvey, EN Drill, VP Balachandran, MI D'Angelica, JA Drebin, ...

Evaluation of progression-free survival as a surrogate endpoint for overall survival in localized pancreatic cancer: Trans-Atlantic Pancreatic Surgery Consortium Study

J Okui, MG Besselink, AC Wei, EM O’Reilly, BG Koerkamp, S Ceuppens, ...

Excellent 2-and 3-Year OS after Ablative MRgRT for Localized Pancreatic Cancer without Surgery

M Reyngold, V Kirichenko, E O'Reilly, M Mcmillan, AJ Wu, PB Romesser, ...

Genomic and biomarker landscape of MTAP deficiency in gastrointestinal cancers.

R Thummalapalli, J Xu, N Tezcan, A Dhyani, OM Fitzpatrick, F Nagib, ...

Genomic evolution of pancreatic cancer at single-cell resolution

Zhang H, Sashittal P, Karnoub ER, Jakatdar A, Umeda S, Hong J, Noronha AM, Cardenas A 3rd, et al.

Genomic landscape and clinical outcomes of MDM2 amplifications in biliary tract cancers.

F Nagib, S Nasir, A Dhyani, R Thummalapalli, DN Khalil, O Heffernan, ...

Genomic predictors of pathologic response to hepatic artery infusion pump chemotherapy in colorectal liver metastases

N Nasar, JF Chou, J Datta, MT Evenhaim, M Gonen, KC Soares, ...

Germline Pathogenic Variants in Homologous Recombination Pathway Genes Are Frequent in Pancreatobiliary Ampullary Carcinoma

Misyura M, Selenica P, Ozcan K, Kemel Y, Basturk O, O'Reilly EM, Reis-Filho JS, Beets-Tan R, et al.

Health-related quality of life (HRQOL) in the phase 3 trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III …

AC Dueck, B Fruth, AC Reinacher-Schick, W Peters, RJ Behrens, C Lieu, ...

Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: Pooled individual patient-level analysis of four clinical trials

M Rousian, R Alessandris, L Schleimer, H Kalvin, O Zaki, L Connell, ...

IL10R Inhibition Induces Neutrophil Tumoricidal Activity

Khalil DN, Gomez R, Regev A, Samaan F, Marouf Y, Budhu S, Hirschhorn D, Schulze I, et al.

Image registration improves inter-reader agreement of objective response in CT assessment of pancreas adenocarcinoma

JS Heiselman, N Horvat, M El Homsi, B Agridag-Ucpinar, O Yildirim, ...

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial

Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, et al.

Investigating Age-Related Differences in Survival Outcomes and Mutation Status of Patients with Intrahepatic Cholangiocarcinoma: M. Armstrong et al.

M Armstrong, H Kalvin, M Gönen, G Abou-Alfa, VP Balachandran, ...

Invigorating pre-existing tumor-infiltrating expandable (TIE) T cell clonotypes in exceptional responders with dual PARP-PD-1 blockade in homologous recombination deficient …

M Hilmi, W Mckerrow, JD Schoenfeld, S Umeda, N Tezcan, C O'Connor, ...

Lycopene and survival in patients with stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702.

S Lee, Q Shi, C Ma, P Kumar, F Couture, JP Kuebler, SS Krishnamurthi, ...

Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial

Reyngold M, Wei AC, O'Reilly EM, D'Angelica MI, Kingham TP, Soares KC, Varghese AM, White C, et al.

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, Shah F, Huq R, Thummalapalli R, Nagib F, Varghese A, et al.

Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer

Kim D, Sim NS, Woo S, Kim MH, Lee CK, Hong SS, Kim SH, Hwang HK, Kang CM, Lee WJ, Jo JH, Chung T, Hwang S, Kang B, Kim JS, Kwon CI, Kim S, Chon HJ, Kim CG, Park YN, Choi HJ

Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancer

Nasca V, Ambrosini M, Taieb J, Cohen R, Lonardi S, Boursi B, Margalit O, Salvatore L, et al.

Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer

W Quan, D Henault, A Zhang, GH Jang, SM Hasnain, D Bevacqua, ...

Mutant allele copy number gains define distinct molecular subtypes of oncogene-driven cancers and are associated with response to allele-specific KRAS G12C inhibitor sotorasib …

MA Perry, AL Richards, A Price, SE Tischfield, H Walch, H Xie, ...

Myofibroblasts Induce Neuroplasticity to Promote Pancreatic Inflammation and Cancer Progression

Nigri J, Lan W, Fung ML, Kayser C, Deschênes A, Hinds J, Kaushalya S, Pawlak SA, et al.

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial

T Macarulla, RP Cid, MS Womack, AC Gracian, A Zervoudakis, H Hatoum, ...

Neoantigen-reactive CD8+ T cell engagement marks exceptional survivors of pancreatic cancer

M Hilmi, JD Schoenfeld, W McKerrow, Y Elhanati, CA O'Connor, S Umeda, ...

NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer

Schram AM, Yang SR, Kahn G, Velasco R, Repetto M, Kinh Gian Do R, DiNapoli S, Sukhadia P, et al.

Oncogene Mutations: The Shared Antigen Vaccines That Work?

R Paredes, SD Haldar, S Pant, EM O'Reilly

Organotropic and genomic characterization of pancreatic neuroendocrine carcinoma.

S Wallam, CJ Kinslow, R Thummalapalli, AA Wallam, DP Horowitz, ...

Outcomes of First Versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma

Nasar N, Armstrong M, Chou JF, Gonen M, Soares KC, Balachandran VP, Drebin JA, Kingham TP, et al.

Pancreatic cancer

Roth S, Apte M, Balachandran VP, Biffi G, Conroy T, Cukierman E, Dotan E, Esposito I, et al.

Pancreatic Cancer—Advances in the Last 50 Years

SG Barreto, A Maitra, EM O'Reilly, D Sahani, R Zheng, CJ Yeo

Pancreatic cancer: advances in immunology, translational analyses and therapeutic paradigms

O'Reilly EM

Pancreatic cancer: advances in immunology, translational analyses and therapeutic paradigms: Pancreatic cancer in 2025

EM O’Reilly

Pancreatic Cancer: Translating Tumor Biology into Actionability

Balogun FO, Sherman MH, Park W, Soares KC, Reyngold M, Schoenfeld JD, Singhal A, Iacobuzio-Donahue CA, et al.

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

W Park, CA O’Connor, JF Chou, M Hilmi, Z Tarcan, C Schwartz, M Larsen, ...

Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer: The POLAR Trial

Park W (Corresponding Author), O’Reilly E, et al.

Phase 1 evaluation of ASP3082, a first-in-class selective protein degrader, in patients (pts) with KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC …

W Park, A Kasi, JW Goldman, M Pelster, B Herzberg, AW Tolcher, AI Spira, ...

Physical activity and molecular residual disease in stage III colon cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80702

GQ Zhang, C Ma, VB Yang, Q Shi, JA Nowak, L Pederson, T Twombly, ...

POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer

Park W, Umeda S, Hilmi M, O'Connor C, Sharma R, Tezcan N, Zhang H, Zhu Y, et al.

Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond

Schürmann H, Park W, O'Kane GM, Sciortino C, Niger M, Reichert M, Olive KP, Pretzell I, et al.

Precision oncology in pancreatic cancer and future treatment directions

L Al Mahmasani, EM O’Reilly